Healthcare news
Immunization, outbreaks, advisories and prevention.
Check the original source before acting.
Teva reports its Teva-Haloperidol (haloperidol) 1 mg tablet is in an actual shortage after a disruption in manufacturing. The actual shortage began Oct 29, 2026 and is estimated to end Nov 30, 2026.
Haloperidol is used for schizophrenia and acute agitation — patients should not stop abruptly and should check stock and alternatives.
Official source: Health Product Shortages Canada (opens in a new tab)
Teva reports its Teva-Haloperidol (haloperidol) 2 mg tablet is in an actual shortage after a disruption in manufacturing. The actual shortage began Oct 29, 2026 and is estimated to end Nov 30, 2026.
Haloperidol is used for schizophrenia and acute agitation — patients should not stop abruptly and should check stock and alternatives.
Official source: Health Product Shortages Canada (opens in a new tab)
Teva reports its Teva-Indomethacin (indomethacin) 25 mg capsule is in an actual shortage after a disruption in manufacturing. The actual shortage began Oct 29, 2026 and is estimated to end Dec 30, 2026.
Indomethacin is an anti-inflammatory drug used for arthritis and gout — patients and pharmacies should check stock and alternatives while the shortage runs.
Official source: Health Product Shortages Canada (opens in a new tab)
Teva reports its Teva-Simvastatin (simvastatin) 20 mg tablet is in an actual shortage after a disruption in manufacturing. The actual shortage began Apr 22, 2026 and no estimated end date is given.
Simvastatin is a widely prescribed cholesterol drug — patients and pharmacies should check stock and alternatives while the shortage runs.
Official source: Health Product Shortages Canada (opens in a new tab)
Teva reports its Teva-Quetiapine XR (quetiapine) 200 mg extended-release tablet is in an actual shortage after a disruption in manufacturing. The actual shortage began Jan 8, 2026 and is estimated to end Nov 30, 2026.
Quetiapine is widely used for schizophrenia, bipolar disorder and depression — patients should not stop abruptly and should check stock and alternatives.
Official source: Health Product Shortages Canada (opens in a new tab)
Teva reports its Teva-Quetiapine XR (quetiapine) 400 mg extended-release tablet is in an actual shortage after a disruption in manufacturing. The actual shortage began Sep 2, 2025 and is estimated to end Nov 30, 2026.
Quetiapine is widely used for schizophrenia, bipolar disorder and depression — patients should not stop abruptly and should check stock and alternatives.
Official source: Health Product Shortages Canada (opens in a new tab)
Teva reports its Teva-Prazosin (prazosin) 1 mg tablet is in an actual shortage after a disruption in manufacturing. The actual shortage began Jun 10, 2026 and no estimated end date is given.
Prazosin is used for blood pressure control and PTSD-related nightmares — patients and pharmacies should check stock and alternatives while the shortage runs.
Official source: Health Product Shortages Canada (opens in a new tab)
Teva reports its Teva-Indomethacin (indomethacin) 50 mg capsule is in an actual shortage after a disruption in manufacturing. The actual shortage began Feb 18, 2026 and is estimated to end Jul 10, 2027.
Indomethacin is an anti-inflammatory drug used for arthritis and gout — patients and pharmacies should check stock and alternatives while the shortage runs.
Official source: Health Product Shortages Canada (opens in a new tab)
Teva reports its Teva-Escitalopram (escitalopram) 10 mg tablet is in an actual shortage after a disruption in manufacturing. The actual shortage began Jun 17, 2026 and is estimated to end Dec 10, 2026.
Escitalopram is a widely prescribed antidepressant — patients should not stop abruptly and should check stock and alternatives with their prescriber and pharmacy.
Official source: Health Product Shortages Canada (opens in a new tab)
Teva reports its Teva-Donepezil (donepezil hydrochloride) 5 mg tablet is in an actual shortage after a disruption in manufacturing. The actual shortage began Jan 30, 2025 and no estimated end date is given.
Donepezil is widely used for Alzheimer's dementia — patients and pharmacies should check stock and alternatives while the shortage runs.
Official source: Health Product Shortages Canada (opens in a new tab)
Sun Pharma reports its Taro-Ramipril (ramipril) 10 mg capsule is in an actual shortage after a disruption in manufacturing. The actual shortage began Dec 3, 2025 and is estimated to end Nov 6, 2026.
Ramipril is a widely prescribed blood pressure drug — patients and pharmacies should check stock and alternatives while the shortage runs.
Official source: Health Product Shortages Canada (opens in a new tab)
Sun Pharma reports its Taro-Pregabalin (pregabalin) 25 mg capsule is in an actual shortage after a disruption in manufacturing. The actual shortage began Oct 6, 2026 and is estimated to end Nov 20, 2026.
Pregabalin is widely used for nerve pain and seizures — patients should not stop abruptly and should check stock and alternatives.
Official source: Health Product Shortages Canada (opens in a new tab)
Sun Pharma reports its Taro-Pregabalin (pregabalin) 50 mg capsule is in an actual shortage after a disruption in manufacturing. The actual shortage began Apr 17, 2026 and is estimated to end Nov 20, 2026.
Pregabalin is widely used for nerve pain and seizures — patients should not stop abruptly and should check stock and alternatives.
Official source: Health Product Shortages Canada (opens in a new tab)
Sun Pharma reports its Taro-Candesartan (candesartan cilexetil) 4 mg tablet is in an actual shortage after a disruption in manufacturing. The actual shortage began Sep 1, 2026 and is estimated to end Nov 6, 2026.
Candesartan is a widely prescribed blood pressure drug — patients and pharmacies should check stock and alternatives while the shortage runs.
Official source: Health Product Shortages Canada (opens in a new tab)
Taro reports its Taro-Testosterone Gel (testosterone) 1% gel is in an actual shortage after a disruption in manufacturing. The actual shortage began Aug 27, 2026 and is estimated to end Nov 20, 2026.
Testosterone gel is used for testosterone replacement therapy — patients and pharmacies should check stock and alternatives while the shortage runs.
Official source: Health Product Shortages Canada (opens in a new tab)
Taro reports its Taro-Lurasidone (lurasidone hydrochloride) 40 mg tablet is in an actual shortage after a disruption in manufacturing. The actual shortage began Jul 1, 2026 and is estimated to end Dec 24, 2026.
Lurasidone is used for schizophrenia and bipolar depression — patients should not stop abruptly and should check stock and alternatives.
Official source: Health Product Shortages Canada (opens in a new tab)
Taro reports its Taro-Desvenlafaxine (desvenlafaxine) 100 mg extended-release tablet is in an actual shortage after a disruption in manufacturing. The actual shortage began May 1, 2026 and is estimated to end Nov 13, 2026.
Desvenlafaxine is a widely prescribed antidepressant — patients should not stop abruptly and should check stock and alternatives.
Official source: Health Product Shortages Canada (opens in a new tab)
Taro reports its Taro-Desvenlafaxine (desvenlafaxine) 50 mg extended-release tablet is in an actual shortage after a disruption in manufacturing. The actual shortage began May 1, 2026 and is estimated to end Nov 13, 2026.
Desvenlafaxine is a widely prescribed antidepressant — patients should not stop abruptly and should check stock and alternatives.
Official source: Health Product Shortages Canada (opens in a new tab)
Taro reports its Taro-Ciprofloxacin/Dexamethasone (ciprofloxacin / dexamethasone) 0.3% / 0.1% otic suspension is in an actual shortage after a disruption in manufacturing. The actual shortage began Mar 4, 2026 and is estimated to end Nov 6, 2026.
Ciprofloxacin/dexamethasone ear drops are widely used for ear infections — patients and pharmacies should check stock and alternatives while the shortage runs.
Official source: Health Product Shortages Canada (opens in a new tab)
QuidelOrtho has identified an issue where certain generations of Vitros chemistry products A1c slides may produce positively biased results. The manufacturer has received 58 complaints regarding this performance issue as of October 15, 2026. No adverse events have been reported to date.
If you use these slides in your lab, contact the manufacturer for further guidance on managing potential result inaccuracies.
Official source: Health Canada recalls and alerts (opens in a new tab)
AbbVie reports its Combigan (timolol / brimonidine tartrate) 0.5% / 0.2% ophthalmic solution is in an actual shortage after a disruption in manufacturing. The actual shortage began Sep 9, 2026 and is estimated to end Dec 11, 2026.
Combigan is a widely used glaucoma eye drop — patients and pharmacies should check stock and alternatives while the shortage runs.
Official source: Health Product Shortages Canada (opens in a new tab)
Glenmark Pharmaceuticals Canada reports its GLN-Olmesartan (olmesartan medoxomil) 40 mg tablet is in an actual shortage that began Oct 29, 2026, driven by an increase in demand. The shortage is estimated to end Nov 27, 2026.
Olmesartan is a widely prescribed blood pressure drug — pharmacies should check stock and alternatives while the shortage runs.
Official source: Health Product Shortages Canada (opens in a new tab)
Glenmark Pharmaceuticals Canada reports its GLN-Olmesartan HCTZ (olmesartan medoxomil / hydrochlorothiazide) 20 mg / 12.5 mg tablet is in an actual shortage that began Oct 29, 2026, driven by an increase in demand. The shortage is estimated to end Nov 27, 2026.
Olmesartan/HCTZ is a widely prescribed blood pressure combination — pharmacies should check stock and alternatives while the shortage runs.
Official source: Health Product Shortages Canada (opens in a new tab)
Pfizer Canada reports its Premarin (conjugated estrogens) 0.625 mg vaginal cream is in an actual shortage after a disruption in manufacturing. The actual shortage began Jun 30, 2026 and no estimated end date is given.
Premarin cream is widely used for menopause-related vaginal symptoms — patients and pharmacies should check stock and alternatives while the shortage runs.
Official source: Health Product Shortages Canada (opens in a new tab)
Bayer reports its Climara 50 (estradiol) 50 mcg transdermal patch is in a Tier 3 critical shortage after an increase in demand. The actual shortage began Sep 18, 2026 and is estimated to end Dec 15, 2026.
Estradiol patches are a mainstay of menopause hormone therapy — a Tier 3 shortage means patients and pharmacies need alternatives or allocation plans now.
Official source: Health Product Shortages Canada (opens in a new tab)
Sandoz Canada reports its Estradot (estradiol) 25 mcg transdermal patch is in a Tier 3 critical shortage after a disruption in manufacturing. The actual shortage began Oct 13, 2026 and is estimated to end Oct 30, 2026.
Estradiol patches are a mainstay of menopause hormone therapy — a Tier 3 shortage means patients and pharmacies need alternatives now.
Official source: Health Product Shortages Canada (opens in a new tab)
Sandoz Canada reports its Estradot (estradiol) 37.5 mcg transdermal patch is in a Tier 3 critical shortage after a disruption in manufacturing. The actual shortage began Oct 13, 2026 and is estimated to end Oct 30, 2026.
Estradiol patches are a mainstay of menopause hormone therapy — a Tier 3 shortage means patients and pharmacies need alternatives now.
Official source: Health Product Shortages Canada (opens in a new tab)
Sandoz Canada reports its Estradot (estradiol) 75 mcg transdermal patch is in a Tier 3 critical shortage after a disruption in manufacturing. The actual shortage began Oct 13, 2026 and is estimated to end Dec 18, 2026.
Estradiol patches are a mainstay of menopause hormone therapy — a Tier 3 shortage means patients and pharmacies need alternatives now.
Official source: Health Product Shortages Canada (opens in a new tab)
Sandoz Canada reports its Estalis (estradiol / norethindrone acetate) 250/50 mcg transdermal patch faces an anticipated Tier 3 shortage from Jan 15, 2027, driven by an increase in demand. The shortage is estimated to end Feb 28, 2027.
Estalis is a combined hormone therapy patch — prescribers and pharmacies should plan supply well ahead of the January start.
Official source: Health Product Shortages Canada (opens in a new tab)
More Canadian provinces are ending seasonal time changes, with Manitoba stopping the clock switch this weekend. Sleep scientists say ending the twice-yearly switch is good for health, but warn that staying on daylight time permanently misaligns with the body's natural clock.
The end of clock changes affects sleep and health for frontline workers on shift schedules — worth knowing which time Manitoba stays on.
News source: CBC News (opens in a new tab)